RespireRx Pharmaceuticals Inc (RSPI)

[senderos]

Really good interview. Margolis represented RSPI quite well.

RespireRx Pharmaceuticals Inc. Announces Video Interview of CFO
BY GlobeNewswire
— 8:45 AM ET 11/04/2021

Glen Rock, N.J., Nov. 04, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. ( RSPI) , (“RespireRx” or the “Company”) a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce the public availability of a video interview of its Senior Vice President, Chief Financial Officer, Treasurer and Secretary, Jeff Margolis, by ProActive Investors.

On Thursday, November 4, 2021, a recorded video interview of Jeff Margolis will be available for viewing by the general public by following this link:

.

The interview will appear on the Proactive Investors website homepage throughout the day on Thursday, November 4, 2021 at www.proactiveinvestors.com and thereafter on the Proactive Investors website by searching for RespireRx at https://www.proactiveinvestors.com/proactive_live and will also be available via link from RespireRx’s website at www.respirerx.com.

Mr. Margolis provided a general introduction to the Company, the nature of the in-process organization of its divisions and planned subsidiaries, and the programs in each of those divisions. Mr. Margolis also provided information about next steps, market opportunities and responded to questions about its intended offering pursuant to Regulation A, the subject of a filed Form 1-A and Form 1-A/A and the related preliminary offering circular which currently indicates a maximum offering amount of 250,000,000 shares of the Company’s common stock, par value $0.001, with an offering price range of $0.02 to $0.03 per share and a maximum offering amount of $7,500,000 and which preliminary offering circular can be accessed at www.sec.gov. The preliminary offering circular is subject to further amendment. No securities may be offered prior to qualification of the offering by the Securities and Exchange Commission or in any jurisdiction in which such offer, solicitation or sale of securities would be unlawful before registration or qualification under the laws of such jurisdiction.

No money or other consideration is being solicited, and if sent, will not be accepted. No offer to buy shares of the Company’s common stock in an offering pursuant to Regulation A can be accepted and no part of the purchase price can be received until the offering statement is qualified, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of its acceptance given after the qualification date. An indication of interest is non-binding and involves no obligation or commitment of any kind. The Offering Statement may be obtained on the Company’s EDGAR page at the following URL: https://www.sec.gov/Archives/edgar/data/849636/000149315221025228/0001493152-21-025228-index.htm.